Rigel Pharmaceuticals says that it has begun a Phase 2 clinical study of its R343 nhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. The 8-week study, called SITAR (SYK Inhibition for Treatment of Asthma with R343), will compare two doses R343 and placebo in approximately 270 adult asthma patients and is expected to be completed in 2013. The dry powder formulation will be delivered using the 3M Taper DPI.
Rigel licensed R343 to AstraZeneca in June 2012.
Read the Rigel press release.
